Register free for our breaking news email alerts with analysis and cutting edge commentary from our award winning team. Registration only takes a minute.

BB Adamant Global Medtech und Services AA Klasse

Ranked 1 out of 34 in - Pharmaceuticals & Health Care over 12 months
All calculations are in CHF unless stated

Managed by

Stefan Blum

Stefan Blum joined Bellevue Asset Management in 2008 and is lead portfolio manager of the BB Adamant Medtech & Services (Lux) Fund. He has 15 years of experience in the healthcare sector. Prior to joining Bellevue Asset Management, he spent four years as head of investor relations at Sonova, the world's largest manufacturer of hearing instruments. As a financial analyst at Bank Sarasin from 1996 to 2000, he covered medical technology and high tech stocks. After that he served as CFO of Obtree Technologies Inc. and advised listed Swiss companies on strategic investor relations issues. Stefan Blum obtained a degree in business administration from the University of St. Gallen and is a graduate of AZEK.

Marcel Fritsch

Marcel Fritsch is a global analyst for medical technology & healthcare services and a senior portfolio manager at Bellevue Asset Management. He is a member of Bellevue’s Healthcare Funds & Mandates team and manages the BB Adamant Medtech & Services (Lux) fund and the BB Adamant Global Medtech & Services (CH) fund. Prior to joining Bellevue in 2008, he was a management consultant with Deloitte Touche Tohmatsu, where he advised multinational companies in the medical technology, pharmaceutical and manufacturing sectors on strategic and operational issues. Fritsch graduated from the University of St. Gallen (HSG), where he earned an MSc in economics.


The primary investment objective of the fund is to generate sustainable long-term capital growth by investing in companies in the medical technology and services sector worldwide. At least two thirds of the fund's assets are invested directly and indirectly in equity securities in the medical technology and services sector. A total of no more than one third of the fund's assets may be invested in instruments, which invest partly but not predominantly in the medical technology and services sector.

Showing fund performance in Switzerland View performance globally


Pharmaceuticals & Health Care over : 30/09/2017 - 30/09/2018

Total Return

Quarterly Performance

to 30/09/2018 Annual Q1 Q2 Q3 Q4
2018 2.0% 15.9% 13.4%
2017 26.5% 9.4% 5.9% 1.6% 7.4%
2016 -2.2% -8.0% 10.9% -1.0% -3.1%
2015 8.6% 8.4% -0.8% -8.0% 9.8%
2014 36.1% 3.2% 2.7% 9.2% 17.7%
2013 18.4% 9.8% -0.5% 1.6% 6.6%
2012 6.9% 9.7% 1.5% 1.7% -5.6%
2011 -9.7% 1.1% -3.4% -10.1% 2.9%
2010 1.5% 7.7% -5.3% -1.2% 0.7%
2009 50.1% 7.3% 16.9% 12.1% 6.7%
2008 -2.9% -0.4% -29.0%

Month by Month Performance

Returns Vs Risk

Registered For Sale In

  1. Switzerland

Fund Info

  • Launch date03/03/2008
  • Share Class size38Mn
  • Base currencyCHF
  • ISIN CH0034334737

Purchase Info

  • Min. initial investment1
  • Min. regular additional investment0


Related News

AA-rated managers: how we’re playing the medtech sector

Bellevue AM's Stefan Blum and Marcel Fritsch reveal how they’re tapping developments in big data, cloud computing and robotics to deliver outperformance.

Bellevue AM launches EM healthcare fund

Asset manager unveils new product designed to build on its global healthcare expertise.

Out of date! How to manage expiring patents in biotech

Bellevue Asset Management reveals the new investment trend in the biotech space amid the wave in patent expiration.

Performance is for the period shown (month end to month end, bid/bid, gross income reinvested, calculated in the currency and currencies indicated).